Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: J Allergy Clin Immunol. 2023 Apr 24;152(3):711–724.e14. doi: 10.1016/j.jaci.2023.04.007

Figure 4. Siglec-9 ligands inhibit mast cell degranulation.

Figure 4.

(A-B) Inhibition of β-hexosaminidase release in LAD2 cells (A) and reduction in LAMP-1 expression in PBCMCs (B) treated with either glycophorin A (GlycA) (25–100 μg/ml) or high molecular weight hyaluronic acid (HMW-HA) (20–100 μg/ml) for 20 min before stimulation. For LAD2 cell IgE-dependent activation, cells were sensitized with IgE (2 μg/ml) overnight and then were challenged with anti-human IgE (500 ng/ml) for 1 h. For PBCMC IgE-dependent activation, cells were treated with anti-FcεRIα antibodies (100 ng/ml) for 20 min. For IgE-independent mast cell activation, LAD2 cells and PBCMCs were stimulated with compound 48/80 (c48/80) (5 μg/ml) for 1 h and 20 min, respectively. Data are shown as mean + SEM. Circles in A (n = 3–4) show values from individual experiments with LAD2 cells. Triangles in B (n = 4–6) show values from individual experiments with cells generated from individual donors. *P < 0.05, **P < 0.01, ***P < 0.001, ****P <0.0001 vs. cells treated with stimuli alone.